• KOL
    • Ruxolitinib Cream
    • Amit G Pandya
    • Amit G Pandya: Influence Statistics

      Amit G Pandya

      Amit G Pandya

      Show email address

      University of Texas Southwestern Medical Center, Dallas, Texas, USA | Palo Alto Foundation Medical Group, Mountain View, CA, USA, and University of Texas Southwestern Medical ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Amit G Pandya:Expert Impact

      Concepts for whichAmit G Pandyahas direct influence:Ruxolitinib cream,Patient registries,Glycolic acid,Topical minoxidil,Pemphigus vulgaris,Treatment melasma,Mycosis fungoides,Pyoderma gangrenosum.

      Amit G Pandya:KOL impact

      Concepts related to the work of other authors for whichfor which Amit G Pandya has influence:Pemphigus vulgaris,Bullous pemphigoid,Mycosis fungoides,Treatment melasma,Tranexamic acid,Skin diseases,Yag laser.

      KOL Resume for Amit G Pandya

      Year
      2022

      University of Texas Southwestern Medical Center, Dallas, Texas, USA

      2021

      Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

      Palo Alto Foundation Medical Group, Mountain View, CA USA

      2020

      Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas

      2019

      Department of Dermatology The University of Texas Southwestern Medical Center Dallas Texas

      2018

      Department of Dermatology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390‐9190, U.S.A

      University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

      2017

      Department of Dermatology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9069, USA

      2016

      Department of Dermatology, Diversity in Health Professions Advisory Committee, University of Texas Southwestern Medical Center, Dallas, Texas

      Diversity Task Force, American Academy of Dermatology, Schaumburg, Illinois

      2015

      University of Texas Southwestern Medical Center Department of Dermatology Dallas TX USA

      2014

      Department of Dermatology, University of Texas Southwestern Medical Center, 5939 Harry Hines Boulevard #300, Dallas, TX 75235, USA

      2013

      Departments of Dermatology, MD Anderson Cancer Center, Houston (Dr Duvic), and UT Southwestern Medical Center, Dallas (Dr Pandya), The University of Texas

      2012

      Correspondence: Amit G. Pandya, MD, Department of Dermatology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9190

      2011

      Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas,

      2009

      From the *Dermatopathology Section, Department of Dermatology, Boston University School of Medicine, Boston, MA; †The Vitiligo and Pigmentation Institute of Southern California, Los Angeles, CA; ‡Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX; and §Galderma Laboratories, L.P., Fort Worth, TX.

      Division of Dermatology, Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

      Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, Tel: +214 648 5770; Fax: +214 648 5777

      2008

      Division of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas

      2007

      Department of Dermatology, University of Texas Southwestern Medical Center at Dallas

      2006

      University of Texas Southwestern Medical Center. Completed as part of Dr High's residency requirements at the University of Texas Southwestern Medical Center

      2005

      From the *Department of Pathology, Division of Hematopathology and †Pittsburgh Cytogenetics Laboratory, University of Pittsburgh Medical Center, Pittsburgh, PA; ‡Department of Dermatology, University of Texas Southwestern, Dallas, TX; and §Rabkin Dermatopathology, Pittsburgh, PA.

      2004

      Department of Dermatology, The University of Texas Southwestern Medical Center,Dallas, Texas, USA

      2003

      Department of Dermatology, The University of Texas, Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75235-9057, USA

      2001

      From the Department of Dermatology, The University of Texas South‐western Medical Center, Dallas, Texas

      2000

      Department of Dermatology (AGP)

      1998

      Department of Dermatology, University of Texas Southwestern Medical Center. Dallas, Texas

      1997

      Dallas and Galveston, Texas

      1996

      From the University of Texas Southwestern Medical Center, Dallas, Texas, USA

      1995

      Department of Dermatology, University of Texas Southwestern Medical Center Dallas, Texas, USA

      1994

      Albuquerque, New Mexico, USA

      1992

      Department of Dermatology, University of Texas Southwestern Medical Center, Dallas 75235-9069.

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Amit G Pandya is among the top experts in the world.
      Concept World rank
      intense preparations administration #1
      halder cutis #1
      follow‐up rituximab #1
      brownskinned patients melasma #1
      homogeneity assessment raters #1
      dermatology cyclophosphamide #1
      regulatory vitiligo scrnaseq #1
      reliability assessment validation #1
      common facial hyperpigmentation #1
      adequate control diseases #1
      boardcertified dermatologists medicine #1
      melasma area #1
      24 weeks cream #1
      hypopigmenation #1
      alakloby #1
      study cream #1
      current literature heterogeneity #1
      severe melasma #1
      skin mucosaltropic viruses #1
      understanding dermatologic diseases #1
      melasma hispanics #1
      process treatment outcome #1
      seborrheic dermatitis hypopigmenation #1
      hyperpigmentation melasma #1
      agents treatment combination #1
      hydroquinone treatment #1
      topical hydroquinone #1
      medical trips #1
      applicants applying #1
      repigmentation rates #1
      article melasqol #1
      maintenance therapy cohort #1
      conference diversity #1
      versicolor vitiligo #1
      melasma daily #1
      faculty rank proportion #1
      masi mexameter scores #1
      melasma chemical peels #1
      severity mmasi #1
      hyperpigmentation common disorder #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Amit G Pandya

      KOL-Index: 17516

      BACKGROUND: To pical minoxidil solution 2% stimulates new hair growth and helps stop the loss of hair in men with androgenetic alopecia and women with female pattern hair loss. Results can be variable, and historic experience suggests that higher concentrations of topical minoxidil may enhance efficacy.

      OBJECTIVE: The purpose of this 48-week, double-blind, placebo-controlled, randomized, multicenter trial was to compare the efficacy and safety of 5% topical minoxidil with 2% topical ...

      Known for Topical Minoxidil | Hair Loss | Female Pattern | Efficacy Safety | Controlled Trial
      KOL-Index: 12477

      OBJECTIVE: To evaluate the efficacy and safety of a novel mechlorethamine hydrochloride, 0.02%, gel in mycosis fungoides. DESIGN Randomized, controlled, observer-blinded, multicenter trial comparing mechlorethamine, 0.02%, gel with mechlorethamine, 0.02%, compounded ointment. Mechlorethamine was applied once daily for up to 12 months. Tumor response and adverse events were assessed every month between months 1 and 6 and every 2 months between months 7 and 12. Serum drug levels were ...

      Known for Mycosis Fungoides | Mechlorethamine Gel | Antineoplastic Agents | Lesion Severity | Composite Assessment
      KOL-Index: 12204

      Although primary cutaneous follicular lymphoma (FL) is considered a distinct variant of FL in the World Health Organization classification ("cutaneous follicle center lymphoma"), its biologic relationship to nodal FL remains controversial. The clinical, morphologic, immunophenotypic, and molecular cytogenetic features of 17 patients with primary cutaneous FL were studied and compared with 16 patients with secondary cutaneous FL. The head and neck region was the most frequent site at ...

      Known for Situ Hybridization | Secondary Cutaneous | Fluorescence Lymphoma | Tumor Chromosomes | Cases Primary
      KOL-Index: 12178

      BACKGROUND: The Melasma Area and Severity Index (MASI), the most commonly used outcome measure for melasma, has not been validated.

      OBJECTIVE: We sought to determine the reliability and validity of the MASI.

      METHODS: After standardized training, 6 raters independently rated 21 patients with mild to severe melasma once daily over a period of 2 days to determine intrarater and interrater reliability. Validation was performed by comparing the MASI with the melasma severity scale. The ...

      Known for Melasma Area | Reliability Assessment | Masi Score | 21 Patients | Hispanic Americans
      KOL-Index: 10497

      Importance: Faculty diversity has important implications for improving the cultural competency and diversity of medical students and residents. However, dermatology is one of the least diverse fields in medicine.

      Objectives: To measure faculty diversity by sex, race, and ethnicity in academic dermatology departments in US medical schools and to evaluate how this representation compares with the diversity of the US population, medical students, department chairs, and faculty in other ...

      Known for Urm Faculty | Diversity Trends | Clinical Departments | Sex Race | Medicine Status
      KOL-Index: 9682

      BACKGROUND: Melasma has been shown to have a significant emotional and psychologic effect on affected patients. Although this pigmentary disorder is thought to be more prevalent among Latinos, the effect of melasma on quality of life (QOL) in this population is unknown.

      OBJECTIVES: The goals of this study were to translate and culturally adapt the previously validated Melasma QOL (MELASQOL) scale into Spanish language, to confirm the new scale's reliability and validity, and to ...

      Known for Life Questionnaire | Melasma Patients | Cultural Adaptation | Hispanic Americans | Melasqol Scale
      KOL-Index: 9216

      Although primary cutaneous diffuse large B-cell lymphomas (DLBCLs) except for those of the leg are grouped together with primary cutaneous follicle center cell lymphoma in the European Organization for Research and Treatment of Cancer classification of primary cutaneous lymphomas, they typically lack the usual phenotypic profile of follicular lymphoma. Whether they are truly of follicular center cell origin, have a molecular pathogenesis similar to nodal follicular lymphoma, or have any ...

      Known for Cell Lymphoma | Secondary Cutaneous | Diffuse Large | Situ Hybridization | Primary Cases
      KOL-Index: 9005

      BACKGROUND: Melasma, also known as mask of pregnancy, is a common, acquired hypermelanosis seen in women with Fitzpatrick skin types II-V, and is often recalcitrant to treatment with depigmentation agents. Glycolic acid has been added to hydroquinone formulations in the past to enhance their depigmentation effects, but may cause irritation, leading to postinflammatory hyperpigmentation.

      AIM: To assess the safety and efficacy of a cream containing 4% hydroquinone, 10% buffered glycolic ...

      Known for Glycolic Acid | Treatment Melasma | 4 Hydroquinone | Pigmentation Mexameter | Common Acquired Hypermelanosis
      KOL-Index: 8985

      A major obstacle in performing multicenter controlled trials for pemphigus is the lack of a validated disease activity scoring system. Here, we assess the reliability and convergent validity of the PDAI (pemphigus disease area index). A group of 10 dermatologists scored 15 patients with pemphigus to estimate the inter- and intra-rater reliability of the PDAI and the recently described ABSIS (autoimmune bullous skin disorder intensity score) instrument. To assess convergent validity, ...

      Known for Convergent Validity | Pdai Absis | Outcome Instruments | Specificity Severity Illness | Pemphigus Disease
      KOL-Index: 8787

      BACKGROUND: Vitiligo is a chronic autoimmune disease resulting in skin depigmentation and reduced quality of life. There is no approved treatment for vitiligo repigmentation and current off-label therapies have limited efficacy, emphasising the need for improved treatment options. We investigated the therapeutic potential of ruxolitinib cream in patients with vitiligo and report the efficacy and safety results up to 52 weeks of double-blind treatment.

      METHODS: We did a multicentre, ...

      Known for Ruxolitinib Cream | Treatment Vitiligo | 3 Patients | Phase 2 | Janus Kinase
      KOL-Index: 8176

      Vitiligo is an autoimmune disease of the skin that results in the destruction of melanocytes and the clinical appearance of white spots. Disease pathogenesis depends on IFN-γ and IFN-γ-induced chemokines to promote T-cell recruitment to the epidermis where melanocytes reside. The skin is a complex organ, with a variety of resident cell types. We sought to better define the microenvironment and distinct cellular contributions during autoimmunity in vitiligo, and we found that the ...

      Known for Disease Vitiligo | Mouse Model | Chemokine Expression | Melanocytes Skin | White Spots
      KOL-Index: 7991

      BackgroundMelasma is an acquired disorder of hyperpigmentation occurring on the face and predominantly affecting women of childbearing age. It is a chronic, often relapsing condition with a negative impact on quality of life. Current treatments for melasma are unsatisfactory.ObjectiveThe aim of this article was to conduct an evidence-based review of interventions available for the treatment of melasma.MethodsA systematic literature search was performed using PubMed and the keywords ...

      Known for Topical Agents | Treatment Melasma | Chemical Peels | Triple Combination Therapy | Evidencebased Review
      KOL-Index: 7946

      BACKGROUND: African Americans with seborrheic dermatitis may manifest associated hypopigmenation. Corticosteroids and antifungals are often used for treatment, yet chronic use of corticosteroids may be associated with skin atrophy, increased intraocular pressure, or further hypopigmenation. Pimecrolimus has been used successfully in a few patients with seborrheic dermatitis.

      OBJECTIVES: This open-label, pilot trial assessed the efficacy and tolerability of pimecrolimus in the treatment ...

      Known for Seborrheic Dermatitis | Pimecrolimus Treatment | Clinical Measures | Skin Atrophy | Inflammatory Agents
      KOL-Index: 7841

      PURPOSE: To assess the effect of minocycline on the ocular flora in patients with acne rosacea or blepharitis.

      METHODS: A total of ten patients were enrolled in this prospective study, with six patients diagnosed with acne rosacea with concomitant meibomianitis, two patients with acne rosacea without concomitant ocular involvement, and two patients with seborrheic blepharitis. The eyelids and conjunctiva of both eyes were cultured before the initiation of systemic minocycline therapy, ...

      Known for Ocular Flora | Acne Rosacea | Eyelids Conjunctiva | Minocycline Therapy | Bacteria Blepharitis
      KOL-Index: 7798

      BACKGROUND: It has been generally believed that the four main causes of melasma are pregnancy, hormonal contraception, family history and sun exposure; however, there are few published comprehensive studies that confirm these assertions. The Pigmentary Disorders Academy - an international group of experts in pigmentary disorders - designed and conducted a global survey of women to investigate the effect of these factors on onset and chronicity of melasma and the course of the disease in ...

      Known for Onset Melasma | Ultraviolet Radiation | Hormonal Influences | Pigmentary Disorders | Sun Exposure

      Key People For Ruxolitinib Cream

      Top KOLs in the world
      #1
      Srdnan Verstovsek
      consultancy funding board directors advisory committees
      #2
      Peggy A Scherle
      prmt5 inhibition prelude therapeutics preclinical characterization
      #3
      Yvonne Y Lo
      janus kinase hepatic impairment preclinical models
      #4
      Stacey Shepard
      janus kinase ruxolitinib cream preclinical characterization
      #5
      James D Rodgers
      hiv protease janus kinase reverse transcriptase
      #6
      Michael D Howell
      atopic dermatitis vaccinia virus eczema herpeticum

      University of Texas Southwestern Medical Center, Dallas, Texas, USA | Palo Alto Foundation Medical Group, Mountain View, CA, USA, and University of Texas Southwestern Medical Center, Dallas, TX, USA | Palo Alto Foundation Medical Group, Sunnyvale, Ca

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.